Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1889-1896

  De Hert, Marc ^a,d   Kalnicka, Dita ^b   Van Winkel, Ruud ^a   Wampers, Martien ^a   Hanssens, Linda ^c   Van Eyck, Dominique ^a   Scheen, Andre ^c   Peuskens, Joseph ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33845999570     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1208     Document Type: Article

References (53)

1. Vaughan CJ, Gotto AM. Update on statins: 2003. Circulation 2004;110:886-892
2. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of 10-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
3. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
4. Task Force Report. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-1503
5. Schuster H, Fox JC. Investigating cardiovascular risk reduction: the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004;5:1187-1200
6. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003;24:1601-1610
7. Grundy SM. The changing face of cardiovascular risk. J Am Coll Cardiol 2005;46:173-175
8. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004;71:195-212
9. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
10. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17
11. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18
12. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93
13. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752
14. Byrne CD, Wild SH. The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Byrne CD, Wild SH, eds. The Metabolic Syndrome. West Sussex, Md: John Wiley & Sons; 2005:1-42
15. Alberti KGMM. Introduction to the metabolic syndrome. Eur Heart J Suppl 2005;7:3-5
16. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-1062
17. International Diabetes Federation. The IDF Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Federation; 2005. Available at: http://www.idf.org/home/index.cfm?unode=1120071E-AACE-41D2-9FA0- BAB6E25BA072. Accessability verified September 25, 2006
18. Scheen AJ. Management of the metabolic syndrome. Minerva Endocrinol 2004;29:31-45
19. Stalenhoef AF, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005;26:2664-2672
20. Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91:3-10
21. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003;92:152-160
22. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-1051
23. Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005;7:430-438
24. Deedwania PC, Hunninghake DB, Bays HE, et al. STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005;95:360-366
25. Resch U, Tatzber F, Budinsky A, et al. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006;61:262-274
26. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565
27. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-508
28. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatry 2001;179:498-502
29. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66(suppl 6):11-20
30. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-28
31. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701
32. Strassnig M, Brar JS, Ganguli R. Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr Res 2005;75:425-432
33. Chue P. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective. Can J Psychiatry 2004;49:200-207
34. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
35. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
36. Osser DN, Najarian DN, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770
37. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3166
38. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a prospective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362
39. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004;58:303-309
40. Yee A, Majumdar SR, Simpson SH, et al. Statin use in type 2 diabetes mellitus is associated with a delay in starting insulin. Diabet Med 2004;21:962-967
41. Paniagua JA, Lopez-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 2002;51:2596-2603
42. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000;150:121-127
43. Lamendola C, Abbasi F, Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005;95:189-193
44. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-888
45. Bottorff MB. Safety and statins: pharmacologic and clinical perspectives. Prev Med Managed Care 2004;4:30-37
46. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002;62:2075-2085; discussion 2086-2087
47. Jeste DV, Gladsjo JA, Lindamer LA, et al. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22:413-430
48. Buckley PF, Miller DD, Singer B. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005;79:281-288
49. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24:1-6
50. De Nayer A, De Hert M, Scheen A, et al. Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int J Psych Clin Pract 2005;9:130-137
51. De Hert M, Van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006;21(suppl 2):S11-S15
52. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
53. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull [Epub ahead of print] Aug 29, 2006